TAEUS Liver demonstrates strong agreement with the industry’s imaging gold standard, MRI‑PDFF, across the full spectrum of steatotic liver disease and patient BMI ANN ARBOR, Mich. / Nov 20, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease (“MASLD”) and... Read More

ANN ARBOR, Mich. / Nov 17, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today provided a business update and reported financial results for the three and nine months ended... Read More

ENDRA is converting static treasury assets into a dynamic rewards engine to support medical innovation ANN ARBOR, Mich. / Nov 13, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today... Read More

Company Officially Launches Digital Asset Treasury Strategy Focused on the Highest Conviction Holdings of Arca Investment Management to Enhance Long-Term Shareholder Value ANN ARBOR, Mich. / Oct 23, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and... Read More

Company Also Intends to Appoint Jeff Dorman to Digital Asset Advisory Board ANN ARBOR, Mich. / Oct 13, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced an aggregate of $4.9... Read More

ANN ARBOR, Mich. / Aug 14, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of T hermo- A coustic E nhanced U ltra S ound (TAEUS ® ), today provided a business update and reported financial results for the three and six months ended June 30, 2025. Business Update Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver system’s probe design... Read More

Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation ANN ARBOR, Mich. / Jun 16, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product... Read More

ANN ARBOR, Mich. / May 15, 2025 / Business Wire / ENDRA Life Sciences Inc . (NASDAQ: NDRA), a pioneer of T hermo- A coustic E nhanced U ltra S ound (TAEUS ® ), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to... Read More

Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA) , a pioneer of T hermo- A coustic E nhanced U ltraSound (TAEUS ® ), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the... Read More

ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of T hermo- A coustic E nhanced U ltraSound (TAEUS ® ), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company’s August 22, 2024, conference... Read More

ANN ARBOR, Mich. / Nov 22, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance... Read More

Company accelerated enrollment in global multisite pilot study and significantly reduced operating expenses while refocusing resources to clinical and regulatory deliverables ANN ARBOR, Mich. / Nov 15, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three and nine months ended September 30, 2024 and provided... Read More

ANN ARBOR, Mich. / Nov 12, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced the acceptance of a poster titled “ Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity ” for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD),... Read More

Global Intellectual Property Portfolio Now Includes 82 Issued Patents ANN ARBOR, Mich. / Nov 06, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.” The ‘282 patent relates to a novel method... Read More

Scans first patient in post-CE mark clinical study with Munich’s center of excellence in Europe’s largest healthcare market ANN ARBOR, Mich. / Oct 22, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one... Read More

ANN ARBOR, Mich. / Aug 28, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price... Read More

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. / Aug 22, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update: New executive team Subsequent to quarter-end, ENDRA... Read More

Shares Expected to Begin Trading on Split-Adjusted Basis on August 20, 2024 ANN ARBOR, Mich. / Aug 16, 2024 / Business Wire / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on August 20,... Read More

ANN ARBOR, Mich. / Aug 13, 2024 / Business Wire / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for... Read More

Board Member Alexander Tokman appointed as acting CEO bringing 24+ years of global commercial leadership experience Two additional industry veterans join in key roles including regulatory and clinical affairs and finance ANN ARBOR, Mich. / Aug 13, 2024 / Business Wire / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced its Board of Directors has... Read More

ANN ARBOR, Mich. / Aug 07, 2024 / Business Wire / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30... Read More

ANN ARBOR, Mich. / Jun 04, 2024 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a... Read More

Increases clarity for ENDRA on regulatory path forward for TAEUS ANN ARBOR, Mich. / May 20, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device... Read More

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. / May 14, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three months ended March 31, 2024 and provided a business update. Highlights from the first quarter of 2024 and recent weeks include: Installed the first TAEUS system in the UK at... Read More

ANN ARBOR, Mich. / May 07, 2024 / Business Wire / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m.... Read More

ENDRA’s IP Portfolio Reaches Milestone of 80 Issued Patents ANN ARBOR, Mich. / May 02, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the issuance of five new patents, including three in Europe and two in China. ENDRA’s intellectual property (IP) portfolio now includes 80 issued patents worldwide, providing protection for the TAEUS system... Read More

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. / Mar 28, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reports financial results for the three months and year ended December 31, 2023 and provides a business update. Highlights from the fourth quarter of 2023 and recent weeks include: Installed first TAEUS system in... Read More

ANN ARBOR, Mich. / Mar 21, 2024 / Business Wire / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at... Read More

King's College Hospital in London Leads UK Introduction of ENDRA Liver System ANN ARBOR, Mich. / Feb 27, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that it has installed a TAEUS liver system at King's College Hospital NHS Foundation Trust (KCH) in London, one of the leading centers of excellence in the United Kingdom's National Health... Read More

Code Complements Important Advancements by the Pharmaceutical Industry and Revised Medical Association Guidelines ANN ARBOR, Mich. / Feb 21, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), welcomes the adoption of the ICD-10 K76.0 code for the diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD). This pivotal update supports recent important... Read More

Global Intellectual Property Portfolio Expands to 74 Issued Patents ANN ARBOR, Mich. / Feb 14, 2024 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection... Read More

Intellectual Property Portfolio Now Stands at 71 Globally Issued Patents ANN ARBOR, Mich. / Nov 29, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No. 11828727 (the ‘727 patent) titled “Thermoacoustic Probe.” The ‘727 patent relates to a... Read More

ANN ARBOR, Mich. / Nov 27, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that management will be participating in The Benchmark Company’s 12 th Annual Discovery One-on-One Investor Conference being held Thursday, December 7, 2023 at the New York Athletic Club in New York City. Management will be holding one-on-one meetings with... Read More

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. / Nov 14, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update. Highlights from the third quarter of 2023 and recent weeks include: Shared positive TAEUS clinical... Read More

Global intellectual property portfolio increases to 70 issued patents ANN ARBOR, Mich. / Nov 08, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the issuance of three new patents, including one in the U.S. and two in China. ENDRA’s intellectual property (IP) portfolio now includes 70 issued patents worldwide, enhancing the IP protection... Read More

ANN ARBOR, Mich. / Nov 07, 2023 / Business Wire / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three and nine months ended September 30, 2023 on Tuesday, November 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning... Read More

ANN ARBOR, Mich. / Nov 06, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced it will host an offsite panel discussion with multidisciplinary experts during the American Association for the Study of Liver Diseases (AASLD) annual meeting, The Liver Meeting, taking place November 10-14, 2023, in Boston. The panel will feature three key... Read More

ANN ARBOR, Mich. / Sep 07, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit ™ 2023 hosted by the European Association for the Study of the Liver (EASL),... Read More

ANN ARBOR, Mich. / Aug 30, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the Company's De Novo request for the TAEUS liver system has advanced to substantive review with the U.S. Food and Drug Administration (FDA). The TAEUS system is ENDRA’s proprietary device that is intended to offer clinicians a tool for... Read More

Global intellectual property portfolio now stands at 67 issued patents ANN ARBOR, Mich. / Aug 23, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the issuance of three new patents, one in the U.S. and two in Europe. ENDRA’s intellectual property portfolio now includes 67 issued patents worldwide, providing protection for the TAEUS ® system... Read More

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. / Aug 14, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three and six months ended June 30, 2023 and provided a business update. Highlights from the second quarter of 2023 and recent weeks include: Submitted a De Novo Request to the... Read More

Announces Positive Topline Data from Clinical Studies Comparing TAEUS with MRI-PDFF ANN ARBOR, Mich. / Aug 14, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for the TAEUS system. The TAEUS system is ENDRA’s proprietary device that... Read More

ANN ARBOR, Mich. / Aug 01, 2023 / Business Wire / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three and six months ended June 30, 2023 on Monday, August 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30... Read More

ANN ARBOR, Mich. / Jul 06, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA) (the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held this morning, was convened and adjourned, without any business being conducted, due to the lack of the required quorum. As a result of the required... Read More

ANN ARBOR, Mich. / Jun 07, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced the acceptance of a poster titled “Thermoacoustic assessment of fatty liver disease - an early clinical feasibility study” for presentation at the International Liver Congress ™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking... Read More

Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, Mich. / May 15, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three months ended March 31, 2023 and provided a business update. Highlights include: Completed enrollment of subjects and data collection for FDA De Novo request, with more than... Read More

ANN ARBOR, Mich. / May 04, 2023 / Business Wire / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three months ended March 31, 2023 on Monday, May 15, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern... Read More

ANN ARBOR, Mich. / May 02, 2023 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today the closing of its previously announced underwritten public offering of 4,312,500 shares of its common stock and warrants to purchase 2,156,250 shares of its common stock, which included the exercise in full by the underwriter of its... Read More

ANN ARBOR, Mich. / Apr 28, 2023 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announced today that it has priced an underwritten public offering of 3,750,000 shares of its common stock and warrants to purchase 1,875,000 shares of its common stock. The warrants are being sold at the rate of one warrant for every two shares of... Read More

ANN ARBOR, Mich. / Mar 14, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three months and year ended December 31, 2022, and provided a business update. Highlights include: Over 100 TAEUS system scans performed at global clinical evaluation sites in 2022 and deployed a new interactive guidance tool. To... Read More

ANN ARBOR, Mich. / Mar 07, 2023 / Business Wire / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three months and year ended December 31, 2022 on Tuesday, March 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at... Read More